<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36258099</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1860-2002</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Molecular imaging and biology</Title><ISOAbbreviation>Mol Imaging Biol</ISOAbbreviation></Journal><ArticleTitle>Head-to-Head Comparison of Tau-PET Radioligands for Imaging TDP-43 in Post-Mortem ALS Brain.</ArticleTitle><Pagination><StartPage>513</StartPage><EndPage>527</EndPage><MedlinePgn>513-527</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11307-022-01779-1</ELocationID><Abstract><AbstractText Label="PURPOSE">In vivo detection of transactivation response element DNA binding protein-43&#xa0;kDa (TDP-43) aggregates through positron emission tomography (PET) would impact the ability to successfully develop therapeutic interventions for a variety of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS).&#xa0; The purpose of the present study is to evaluate the ability of six tau PET radioligands to bind to TDP-43 aggregates in post-mortem brain tissues from ALS patients.</AbstractText><AbstractText Label="PROCEDURES">Herein, we report the first head-to-head evaluation of six tritium labeled isotopologs of tau-targeting PET radioligands, [<sup>3</sup>H]MK-6240 (a.k.a. florquinitau), [<sup>3</sup>H]Genentech Tau Probe-1 (GTP-1), [<sup>3</sup>H]JNJ-64326067(JNJ-067), [<sup>3</sup>H]CBD-2115, [<sup>3</sup>H]flortaucipir, and [<sup>3</sup>H]APN-1607, and their ability to bind to the &#x3b2;-pleated sheet structures of aggregate TDP-43 in post-mortem ALS brain tissues by autoradiography and immunostaining methods. Post-mortem frontal cortex, motor cortex, and cerebellum tissues were evaluated, and binding intensity was aligned with areas of elevated phosphorylated tau (ptau), pTDP-43, and &#x3b2;-amyloid.</AbstractText><AbstractText Label="RESULTS">Negligible binding was observed with [<sup>3</sup>H]MK-6240, [<sup>3</sup>H]JNJ-067, and [<sup>3</sup>H]GTP-1. While [<sup>3</sup>H]CBD-2115 displayed marginal specific binding, this binding did not significantly correlate with the distribution of pTDP-43 and AT8 inclusions. Of the remaining ligands, the distribution of [<sup>3</sup>H]flortaucipir did not significantly correlate to pTDP-43 pathology; however, specific binding trends to a positive relationship with tau. Finally, [<sup>3</sup>H]APN-1607 relates most strongly to amyloid load and does not indicate pTDP-43 pathology as confirmed by [<sup>3</sup>H]PiB distribution in sister sections.</AbstractText><AbstractText Label="CONCLUSIONS">Our results demonstrate the prominent nature of mixed pathology in ALS, and do not support the application of [<sup>3</sup>H]MK-6240, [<sup>3</sup>H]JNJ-067, [<sup>3</sup>H]GTP-1, [<sup>3</sup>H]CBD-2115, [<sup>3</sup>H]flortaucipir, or [<sup>3</sup>H]APN-1607 for selective imaging TDP-43 in ALS for clinical research with the currently available in vitro data. Identification of potent and selective radiotracers for TDP-43 remains an ongoing challenge.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to World Molecular Imaging Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Knight</LastName><ForeName>Ashley C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre for Addiction and Mental Health, 250 College Street, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Science, University of Toronto, 1 King's College Circle, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Morrone</LastName><ForeName>Christopher D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre for Addiction and Mental Health, 250 College Street, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varlow</LastName><ForeName>Cassis</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre for Addiction and Mental Health, 250 College Street, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Science, University of Toronto, 1 King's College Circle, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Wai Haung</ForeName><Initials>WH</Initials><AffiliationInfo><Affiliation>Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre for Addiction and Mental Health, 250 College Street, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Toxicology, University of Toronto, 1 King's College Circle, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McQuade</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Takeda Pharmaceutical Company, Ltd, 35 Landsdowne Street, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasdev</LastName><ForeName>Neil</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-2087-5125</Identifier><AffiliationInfo><Affiliation>Azrieli Centre for Neuro-Radiochemistry, Brain Health Imaging Centre, Centre for Addiction and Mental Health, 250 College Street, Toronto, Canada. Neil.Vasdev@UToronto.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Science, University of Toronto, 1 King's College Circle, Toronto, Canada. Neil.Vasdev@UToronto.ca.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, 250 College Street, Toronto, Canada. Neil.Vasdev@UToronto.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AG054473</GrantID><Acronym>RG</Acronym><Agency>CSR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AG052414</GrantID><Acronym>RG</Acronym><Agency>CSR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Imaging Biol</MedlineTA><NlmUniqueID>101125610</NlmUniqueID><ISSNLinking>1536-1632</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>86-01-1</RegistryNumber><NameOfSubstance UI="D006160">Guanosine Triphosphate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006160" MajorTopicYN="N">Guanosine Triphosphate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">APN-1607</Keyword><Keyword MajorTopicYN="N">Autoradiographyz</Keyword><Keyword MajorTopicYN="N">Flortaucipir</Keyword><Keyword MajorTopicYN="N">MK-6240</Keyword><Keyword MajorTopicYN="N">PET</Keyword><Keyword MajorTopicYN="N">Radioligand binding</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">Tau</Keyword><Keyword MajorTopicYN="N">&#x3b2;-Amyloid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>12</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>18</Day><Hour>23</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36258099</ArticleId><ArticleId IdType="doi">10.1007/s11307-022-01779-1</ArticleId><ArticleId IdType="pii">10.1007/s11307-022-01779-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chi&#xf2; A, Logroscino G, Traynor BJ et al (2013) Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41:118&#x2013;130. https://doi.org/10.1159/000351153</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Martinez-Lage M, Robinson J et al (2009) Clinical and pathological continuum of multisystem TDP-43 proteinopathies. Arch Neurol 66:180&#x2013;189. https://doi.org/10.1001/archneurol.2008.558</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2008.558</ArticleId><ArticleId IdType="pubmed">19204154</ArticleId><ArticleId IdType="pmc">2774117</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Chi&#xf2; A, Traynor BJ (2014) State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17:17&#x2013;23. https://doi.org/10.1038/nn.3584</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.3584</ArticleId><ArticleId IdType="pubmed">24369373</ArticleId></ArticleIdList></Reference><Reference><Citation>Majumder V, Gregory JM, Barria MA et al (2018) TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. BMC Neurol 18:90. https://doi.org/10.1186/s12883-018-1091-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-018-1091-7</ArticleId><ArticleId IdType="pubmed">29954341</ArticleId><ArticleId IdType="pmc">6027783</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK et al (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314:130&#x2013;133. https://doi.org/10.1126/science.1134108</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H et al (2006) TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun 351:602&#x2013;611. https://doi.org/10.1016/j.bbrc.2006.10.093</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Gray E, Ansorge O et al (2018) Towards a TDP-43-based biomarker for ALS and FTLD. Mol Neurobiol 55:7789&#x2013;7801. https://doi.org/10.1007/s12035-018-0947-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-0947-6</ArticleId><ArticleId IdType="pubmed">29460270</ArticleId><ArticleId IdType="pmc">6132775</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, Botond G, Budka H (2010) Protein coding of neurodegenerative dementias: the neuropathological basis of biomarker diagnostics. Acta Neuropathol 119:389&#x2013;408. https://doi.org/10.1007/s00401-010-0658-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0658-1</ArticleId><ArticleId IdType="pubmed">20198481</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB et al (2013) Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 74:20&#x2013;38. https://doi.org/10.1002/ana.23937</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId><ArticleId IdType="pmc">3785076</ArticleId></ArticleIdList></Reference><Reference><Citation>Tamara Seredenina P (2019) Discovery and development of diagnostics and therapeutics for TDP-43 proteinopathies. Lisbon, Portugal</Citation></Reference><Reference><Citation>Brooks A, Tanzey S, Shao X, Scott P (2018) Binding potential of radioligand [18F]FL2-b by autoradiography in amyotrophic lateral sclerosis and lewy body dementia. J Nucl Med 59:613</Citation></Reference><Reference><Citation>Tanzey S, Brooks A, Shao X, Scott P (2020) Extraction of enriched phosphorylated TDP43 from ALS tissue for evaluation of new TDP-43 radiotracers. J Nucl Med 61:1038&#x2013;1038</Citation></Reference><Reference><Citation>Kassubek J, Pagani M (2019) Imaging in amyotrophic lateral sclerosis: MRI and PET. Curr Opin Neurol 32:740&#x2013;746. https://doi.org/10.1097/wco.0000000000000728</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/wco.0000000000000728</ArticleId><ArticleId IdType="pubmed">31335337</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada R, Okamura N, Furumoto S, Yanai K (2018) Imaging protein misfolding in the brain using &#x3b2;-sheet ligands. Front Neurosci 12. https://doi.org/10.3389/fnins.2018.00585</Citation></Reference><Reference><Citation>Klunk WE, Wang Y, Huang GF, et al (2001) Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. In: Life Sci. Netherlands, pp 1471&#x2013;84</Citation></Reference><Reference><Citation>Mathis CA, Mason NS, Lopresti BJ, Klunk WE (2012) Development of positron emission tomography &#x3b2;-amyloid plaque imaging agents. Semin Nucl Med 42:423&#x2013;432</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.semnuclmed.2012.07.001</ArticleId><ArticleId IdType="pubmed">23026364</ArticleId><ArticleId IdType="pmc">3520098</ArticleId></ArticleIdList></Reference><Reference><Citation>Leuzy A, Chiotis K, Lemoine L et al (2019) Tau PET imaging in neurodegenerative tauopathies&#x2014;still a challenge. Mol Psychiatry 24:1112&#x2013;1134. https://doi.org/10.1038/s41380-018-0342-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-018-0342-8</ArticleId><ArticleId IdType="pubmed">30635637</ArticleId><ArticleId IdType="pmc">6756230</ArticleId></ArticleIdList></Reference><Reference><Citation>Jucker M, Walker LC (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501:45&#x2013;51. https://doi.org/10.1038/nature12481</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature12481</ArticleId><ArticleId IdType="pubmed">24005412</ArticleId><ArticleId IdType="pmc">3963807</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigio EH, Wu JY, Deng HX et al (2013) Inclusions in frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) and amyotrophic lateral sclerosis (ALS), but not FTLD with FUS proteinopathy (FTLD-FUS), have properties of amyloid. Acta Neuropathol 125:463&#x2013;465</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1089-6</ArticleId><ArticleId IdType="pubmed">23378033</ArticleId><ArticleId IdType="pmc">3593646</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong LK, Uryu K, Trojanowski JQ, Lee VM-Y (2008) TDP-43 proteinopathies: neurodegenerative protein misfolding diseases without amyloidosis. Neurosignals 16:41&#x2013;51. https://doi.org/10.1159/000109758</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000109758</ArticleId><ArticleId IdType="pubmed">18097159</ArticleId></ArticleIdList></Reference><Reference><Citation>Mompe&#xe1;n M, Herv&#xe1;s R, Xu Y et al (2015) Structural evidence of amyloid fibril formation in the putative aggregation domain of TDP-43. J Phys Chem Lett 6:2608&#x2013;2615. https://doi.org/10.1021/acs.jpclett.5b00918</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jpclett.5b00918</ArticleId><ArticleId IdType="pubmed">26266742</ArticleId><ArticleId IdType="pmc">5568655</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Geser F, Stieber A, et al (2013) TDP-43 skeins show properties of amyloid in a subset of ALS cases. ActaNeuropathol 121&#x2013;131. https://doi.org/10.1007/s00401-012-1055-8</Citation></Reference><Reference><Citation>Li Q, Babinchak WM, Surewicz WK (2021) Cryo-EM structure of amyloid fibrils formed by the entire low complexity domain of TDP-43. Nat Commun 12:1620. https://doi.org/10.1038/s41467-021-21912-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21912-y</ArticleId><ArticleId IdType="pubmed">33712624</ArticleId><ArticleId IdType="pmc">7955110</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Q, Boyer DR, Sawaya MR et al (2019) Cryo-EM structures of four polymorphic TDP-43 amyloid cores. Nat Struct Mol Biol 26:619&#x2013;627. https://doi.org/10.1038/s41594-019-0248-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-019-0248-4</ArticleId><ArticleId IdType="pubmed">31235914</ArticleId><ArticleId IdType="pmc">7047951</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevan-Jones WR, Cope TE, Jones PS et al (2018) [<sup>18</sup>F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia. J Neurol Neurosurg Psychiatry 89:1032&#x2013;1037. https://doi.org/10.1136/jnnp-2017-316402</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-316402</ArticleId><ArticleId IdType="pubmed">28912300</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia C-F, Arteaga J, Chen G et al (2013) [<sup>18</sup>F]T807, a novel tau positron emission tomography imaging agent for Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement 9:666&#x2013;676. https://doi.org/10.1016/j.jalz.2012.11.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2012.11.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Hostetler ED, Walji AM, Zeng Z et al (2016) Preclinical characterization of <sup>18</sup>F-MK-6240, a promising PET tracer for in vivo quantification of human neurofibrillary tangles. J Nucl Med 57:1599&#x2013;1606. https://doi.org/10.2967/jnumed.115.171678</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.115.171678</ArticleId><ArticleId IdType="pubmed">27230925</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt ME, Janssens L, Moechars D et al (2020) Clinical evaluation of [<sup>18</sup>F] JNJ-64326067, a novel candidate PET tracer for the detection of tau pathology in Alzheimer&#x2019;s disease. Eur J Nucl Med Mol Imaging 47:3176&#x2013;3185. https://doi.org/10.1007/s00259-020-04880-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-04880-1</ArticleId><ArticleId IdType="pubmed">32535652</ArticleId><ArticleId IdType="pmc">7680304</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanabria Bohorquez S, Marik J, Ogasawara A et al (2019) [<sup>18</sup>F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer&#x2019;s disease. Eur J Nucl Med Mol Imaging 46:2077&#x2013;2089. https://doi.org/10.1007/s00259-019-04399-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-019-04399-0</ArticleId><ArticleId IdType="pubmed">31254035</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimada H, Kitamura S, Ono M et al (2017) [IC-P-198]: First-in-human PET study with <sup>18</sup>F-AM-PBB3 and <sup>18</sup>F-PM-PBB3. Alzheimer&#x2019;s Dement 13:P146&#x2013;P146. https://doi.org/10.1016/j.jalz.2017.06.2573</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2017.06.2573</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindberg A, Knight AC, Sohn D et al (2021) Radiosynthesis, in vitro and in vivo evaluation of [<sup>18</sup>F]CBD-2115 as a first-in-class radiotracer for imaging 4R-tauopathies. ACS Chem Neurosci 12:596&#x2013;602. https://doi.org/10.1021/acschemneuro.0c00801</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00801</ArticleId><ArticleId IdType="pubmed">33497190</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn D (2019) Selective ligands for tau aggregates. WIPOI Bureau, Karen and Sten Mortstedt CBD Solutions AB.</Citation></Reference><Reference><Citation>Ono M, Sahara N, Kumata K et al (2017) Distinct binding of PET ligands PBB3 and AV-1451 to tau fibril strains in neurodegenerative tauopathies. Brain 140:764&#x2013;780. https://doi.org/10.1093/brain/aww339</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww339</ArticleId><ArticleId IdType="pubmed">28087578</ArticleId><ArticleId IdType="pmc">5837223</ArticleId></ArticleIdList></Reference><Reference><Citation>Tagai K, Ono M, Kubota M et al (2021) High-contrast in vivo imaging of tau pathologies in Alzheimer&#x2019;s and non-Alzheimer&#x2019;s disease tauopathies. Neuron 109:42-58.e8. https://doi.org/10.1016/j.neuron.2020.09.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2020.09.042</ArticleId><ArticleId IdType="pubmed">33125873</ArticleId></ArticleIdList></Reference><Reference><Citation>Murugan NA, Nordberg A, &#xc5;gren H (2018) Different positron emission tomography tau tracers bind to multiple binding sites on the tau fibril: insight from computational modeling. ACS Chem Neurosci 9:1757&#x2013;1767. https://doi.org/10.1021/acschemneuro.8b00093</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.8b00093</ArticleId><ArticleId IdType="pubmed">29630333</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowe CC, Pejoska S, Mulligan RS et al (2013) Head-to-head comparison of <sup>11</sup>C-PiB and <sup>18</sup>F-AZD4694 (NAV4694) for &#x3b2;-amyloid imaging in aging and dementia. J Nucl Med 54:880&#x2013;886. https://doi.org/10.2967/jnumed.112.114785</Citation><ArticleIdList><ArticleId IdType="doi">10.2967/jnumed.112.114785</ArticleId><ArticleId IdType="pubmed">23575995</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Santillo AF, Wald&#xf6; ML et al (2019) <sup>18</sup>F-Flortaucipir in TDP-43 associated frontotemporal dementia. Sci Rep 9:6082. https://doi.org/10.1038/s41598-019-42625-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-42625-9</ArticleId><ArticleId IdType="pubmed">30988363</ArticleId><ArticleId IdType="pmc">6465310</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai RM, Bejanin A, Lesman-Segev O et al (2019) 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimer&#x2019;s Res Ther 11:13. https://doi.org/10.1186/s13195-019-0470-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13195-019-0470-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Marqui&#xe9; M, Normandin MD, Vanderburg CR et al (2015) Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 78:787&#x2013;800. https://doi.org/10.1002/ana.24517</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24517</ArticleId><ArticleId IdType="pubmed">26344059</ArticleId><ArticleId IdType="pmc">4900162</ArticleId></ArticleIdList></Reference><Reference><Citation>Sander K, Lashley T, Gami P et al (2016) Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer&#x2019;s disease, primary tauopathies, and other dementias. Alzheimer&#x2019;s Dement 12:1116&#x2013;1124. https://doi.org/10.1016/j.jalz.2016.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jalz.2016.01.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe VJ, Curran G, Fang P et al (2016) An autoradiographic evaluation of AV-1451 Tau PET in dementia. Acta Neuropathol Commun 4:58. https://doi.org/10.1186/s40478-016-0315-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0315-6</ArticleId><ArticleId IdType="pubmed">27296779</ArticleId><ArticleId IdType="pmc">4906968</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Li J, Nordberg A, &#xc5;gren H (2021) Dissecting the binding profile of PET tracers to corticobasal degeneration tau fibrils. ACS Chem Neurosci 12:3487&#x2013;3496. https://doi.org/10.1021/acschemneuro.1c00536</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.1c00536</ArticleId><ArticleId IdType="pubmed">34464084</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemoine L, Leuzy A, Chiotis K et al (2018) Tau positron emission tomography imaging in tauopathies: the added hurdle of off-target binding. Alzheimer&#x2019;s Dement 10:232&#x2013;236. https://doi.org/10.1016/j.dadm.2018.01.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2018.01.007</ArticleId></ArticleIdList></Reference><Reference><Citation>Vermeiren C, Motte P, Viot D et al (2018) The tau positron-emission tomography tracer AV-1451 binds with similar affinities to tau fibrils and monoamine oxidases. Mov Disord 33:273&#x2013;281. https://doi.org/10.1002/mds.27271</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27271</ArticleId><ArticleId IdType="pubmed">29278274</ArticleId></ArticleIdList></Reference><Reference><Citation>Jie CVML, Treyer V, Schibli R, Mu L (2021) Tauvid<sup>TM</sup>: The first FDA-approved PET tracer for imaging tau pathology in Alzheimer&#x2019;s disease. Pharmaceuticals 14. https://doi.org/10.3390/ph14020110</Citation></Reference><Reference><Citation>Jossan SS, Ekblom J, Aquilonius SM, Oreland L (1994) Monoamine oxidase-B in motor cortex and spinal cord in amyotrophic lateral sclerosis studied by quantitative autoradiography. J Neural Transm Suppl 41:243&#x2013;248. https://doi.org/10.1007/978-3-7091-9324-2_31</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-7091-9324-2_31</ArticleId><ArticleId IdType="pubmed">7931232</ArticleId></ArticleIdList></Reference><Reference><Citation>James ML, Gambhir SS (2012) A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev 92:897&#x2013;965. https://doi.org/10.1152/physrev.00049.2010</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00049.2010</ArticleId><ArticleId IdType="pubmed">22535898</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright JP, Goodman JR, Lin Y-G et al (2022) Monoamine oxidase binding not expected to significantly affect [18F]flortaucipir PET interpretation. Eur J Nucl Med Mol Imaging 49:3797&#x2013;3808. https://doi.org/10.1007/s00259-022-05822-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-022-05822-9</ArticleId><ArticleId IdType="pubmed">35596745</ArticleId><ArticleId IdType="pmc">9399028</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Fu J, Yu J et al (2020) Tau PET imaging with [18F]PM-PBB3 in frontotemporal dementia with MAPT mutation. J Alzheimers Dis 76:149&#x2013;157. https://doi.org/10.3233/jad-200287</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/jad-200287</ArticleId><ArticleId IdType="pubmed">32444551</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohta Y, Shimada H, Ikegami K et al (2021) A case of Kii amyotrophic lateral sclerosis/parkinsonism dementia complex presenting as progressive parkinsonism with corresponding tau imaging. Neurol Clin Neurosci 9:124&#x2013;126. https://doi.org/10.1111/ncn3.12463</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ncn3.12463</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Murzin AG, Falcon B et al (2021) Cryo-EM structures of tau filaments from Alzheimer&#x2019;s disease with PET ligand APN-1607. Acta Neuropathol 141:697&#x2013;708. https://doi.org/10.1007/s00401-021-02294-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02294-3</ArticleId><ArticleId IdType="pubmed">33723967</ArticleId><ArticleId IdType="pmc">8043864</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez-Soriano A, Arena JE, Dinelle K et al (2017) PBB3 imaging in Parkinsonian disorders: evidence for binding to tau and other proteins. Mov Disord 32:1016&#x2013;1024. https://doi.org/10.1002/mds.27029</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27029</ArticleId><ArticleId IdType="pubmed">28568506</ArticleId></ArticleIdList></Reference><Reference><Citation>Miranda-Azpiazu P, Svedberg M, Higuchi M et al (2020) Identification and in vitro characterization of C05&#x2013;01, a PBB3 derivative with improved affinity for alpha-synuclein. Brain Res 1749:147131. https://doi.org/10.1016/j.brainres.2020.147131</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2020.147131</ArticleId><ArticleId IdType="pubmed">32956648</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S, Ono M, Sahara N et al (2017) Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to &#x3b1;-synuclein pathology. Mov Disord 32:884&#x2013;892. https://doi.org/10.1002/mds.27013</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.27013</ArticleId><ArticleId IdType="pubmed">28440890</ArticleId><ArticleId IdType="pmc">5577807</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S, Zhang Z, Ang LC (2020) Clinicopathological overlap of neurodegenerative diseases: a comprehensive review. J Clin Neurosci 78:30&#x2013;33. https://doi.org/10.1016/j.jocn.2020.04.088</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2020.04.088</ArticleId><ArticleId IdType="pubmed">32354648</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda T (2018) Possible concurrence of TDP-43, tau and other proteins in amyotrophic lateral sclerosis/frontotemporal lobar degeneration. Neuropathology 38:72&#x2013;81. https://doi.org/10.1111/neup.12428</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/neup.12428</ArticleId><ArticleId IdType="pubmed">28960544</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton RL, Bowser R (2004) Alzheimer disease pathology in amyotrophic lateral sclerosis. Acta Neuropathol 107:515&#x2013;522. https://doi.org/10.1007/s00401-004-0843-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-004-0843-1</ArticleId><ArticleId IdType="pubmed">15024584</ArticleId></ArticleIdList></Reference><Reference><Citation>Behrouzi R, Liu X, Wu D et al (2016) Pathological tau deposition in motor neurone disease and frontotemporal lobar degeneration associated with TDP-43 proteinopathy. Acta Neuropathol Commun 4:33. https://doi.org/10.1186/s40478-016-0301-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0301-z</ArticleId><ArticleId IdType="pubmed">27036121</ArticleId><ArticleId IdType="pmc">4818389</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyoo CH, Cho H, Choi JY et al (2016) (2016) Tau accumulation in primary motor cortex of variant Alzheimer&#x2019;s disease with spastic paraparesis. J Alzheimers Dis 51:671&#x2013;675. https://doi.org/10.3233/JAD-151052</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-151052</ArticleId><ArticleId IdType="pubmed">26890779</ArticleId></ArticleIdList></Reference><Reference><Citation>Arseni D, Hasegawa M, Murzin AG et al (2022) Structure of pathological TDP-43 filaments from ALS with FTLD. Nature 601:139&#x2013;143. https://doi.org/10.1038/s41586-021-04199-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04199-3</ArticleId><ArticleId IdType="pubmed">34880495</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>